Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Recurrence Prevention

  • Home
  • Recurrence Prevention
Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence
Posted innews Oncology Specialties

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence

Posted by MedXY By MedXY 09/04/2025
A phase 2 randomized trial demonstrates that targeting dormant disseminated tumor cells with hydroxychloroquine and everolimus is safe, feasible, and reduces minimal residual disease, potentially improving recurrence-free survival in breast cancer survivors.
Read More
Berberine Demonstrates Long-Term Prevention of Colorectal Adenoma Recurrence: A Six-Year Follow-Up Study
Posted inClinical Updates Gastroenterology Specialties

Berberine Demonstrates Long-Term Prevention of Colorectal Adenoma Recurrence: A Six-Year Follow-Up Study

Posted by MedXY By MedXY 08/23/2025
Berberine shows sustained efficacy and safety in reducing colorectal adenoma recurrence and neoplasm occurrence after polypectomy, providing new directions for secondary prevention of colorectal cancer.
Read More
  • Tumor Morcellation, Not Minimally Invasive Surgery Alone, Drives Worse Disease-Free Survival in Stage I Adult Granulosa Cell and Sertoli-Leydig Cell Tumors
  • Phenotyping Preeclampsia Using Unsupervised Machine Learning: A Prospective Cohort Study
  • Severe Maternal Morbidity at Delivery Is Linked to Shorter and Less Exclusive Breastfeeding in Nulliparous U.S. Patients
  • Adult Liver Transplant Candidate Evaluation: What the New AASLD/AST Guideline Changes
  • TNF-α–Driven Immune-Endothelial Injury Emerges as a Therapeutic Target in Severe Acute Pancreatitis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in